Berapakah harga POINT Biopharma Global Inc. (PNT)

Harga POINT Biopharma Global Inc. (PNT) adalah $12.50

Apakah topi pasaran POINT Biopharma Global Inc. (PNT)

Cap pasaran POINT Biopharma Global Inc. (PNT) adalah $708.42M

Hasil POINT Biopharma Global Inc. (PNT)

POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors. Beyond these late-stage programs, the company's pipeline includes earlier-stage product candidates such as PNT2001, a next-generation PSMA-targeting agent undergoing preclinical studies for non-metastatic castration-sensitive prostate cancer, and PNT-2004, a program focused on fibroblast activation protein-alpha (FAP-a) with broad potential across multiple tumor types, also in preclinical development. Additionally, POINT Biopharma is actively developing further drug candidates utilizing its CanSEEK technology, which it has sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited. The company was established in 2019 and is headquartered in Indianapolis, Indiana.

Tahun	Hasil	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Hasil

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Hasil	Perbezaan Hasil	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.74B	-	AU
Moderna, Inc. MRNA.US	$2.23B	-	US
Lonza Group AG LONN.SW	-	-	CH

Syarikat

Hasil

Perbezaan Hasil

Negara